316 related articles for article (PubMed ID: 22460789)
1. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
[TBL] [Abstract][Full Text] [Related]
2. Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer.
Liu JC; Zacksenhouse M; Eisen A; Nofech-Mozes S; Zacksenhaus E
PLoS One; 2017; 12(6):e0179223. PubMed ID: 28632792
[TBL] [Abstract][Full Text] [Related]
3. A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.
Liu JC; Egan SE; Zacksenhaus E
Oncotarget; 2013 Aug; 4(8):1317-28. PubMed ID: 23945331
[TBL] [Abstract][Full Text] [Related]
4. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
5. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
7. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
[TBL] [Abstract][Full Text] [Related]
8. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
9. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
Nakanishi T; Chumsri S; Khakpour N; Brodie AH; Leyland-Jones B; Hamburger AW; Ross DD; Burger AM
Br J Cancer; 2010 Mar; 102(5):815-26. PubMed ID: 20145614
[TBL] [Abstract][Full Text] [Related]
10. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
[TBL] [Abstract][Full Text] [Related]
12. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Pandya K; Wyatt D; Gallagher B; Shah D; Baker A; Bloodworth J; Zlobin A; Pannuti A; Green A; Ellis IO; Filipovic A; Sagert J; Rana A; Albain KS; Miele L; Denning MF; Osipo C
Clin Cancer Res; 2016 Jan; 22(1):175-86. PubMed ID: 26350262
[TBL] [Abstract][Full Text] [Related]
13. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
14. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
16. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
Tanioka M; Sakai K; Sudo T; Sakuma T; Kajimoto K; Hirokaga K; Takao S; Negoro S; Minami H; Nakagawa K; Nishio K
Breast Cancer Res Treat; 2014 Oct; 147(3):513-25. PubMed ID: 25200445
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
19. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
